News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
16,830 Results
Type
Article (878)
Company Profile (17)
Press Release (15933)
Multimedia
Podcasts (2)
Webinars (2)
Section
Business (6634)
Career Advice (17)
Deals (721)
Drug Delivery (2)
Drug Development (2458)
Employer Resources (2)
FDA (257)
Job Trends (316)
News (8973)
Policy (414)
Tag
2027 Bio NC Standard (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (1)
Academia (40)
Accelerated approval (3)
ADA (2)
Adcomms (5)
Allergies (7)
Alliances (1268)
ALS (1)
Alzheimer's disease (30)
Antibody-drug conjugate (ADC) (41)
Approvals (260)
Artificial intelligence (16)
ASCO (10)
Autoimmune disease (23)
Automation (1)
Bankruptcy (3)
Belgium (1)
Best Places to Work (257)
BIO (3)
Biologics (2)
BIOSECURE Act (5)
Biosimilars (3)
Biotechnology (14)
Bladder cancer (1)
Brain cancer (1)
Breast cancer (8)
Cancer (220)
Cardiovascular disease (16)
Career advice (10)
CAR-T (19)
CDC (1)
CDMO (4)
Celiac Disease (1)
Cell therapy (84)
Clinical research (2071)
Collaboration (93)
Commercialization (1)
Compensation (60)
Complete response letters (8)
COVID-19 (103)
CRISPR (7)
C-suite (85)
Cystic fibrosis (1)
Data (310)
Depression (1)
Dermatology (5)
Diabetes (30)
Diagnostics (64)
Digital health (1)
Drug discovery (15)
Drug pricing (1)
Duchenne muscular dystrophy (1)
Earnings (1828)
Editorial (3)
Employer resources (2)
Events (2851)
Executive appointments (68)
FDA (381)
Fibrodysplasia Ossificans Progressiva (2)
Frontotemporal dementia (2)
Funding (88)
Gene editing (12)
Gene therapy (50)
GLP-1 (20)
Government (51)
Guidances (12)
Healthcare (512)
Hematology (7)
Huntington's disease (1)
Immunology and inflammation (20)
Immuno-oncology (4)
Indications (6)
Infectious disease (109)
Inflammatory bowel disease (19)
Intellectual property (6)
Interviews (3)
IPO (415)
Job creations (65)
Job search strategy (10)
JPM (2)
Kidney cancer (1)
Kidney disease (2)
Labor market (5)
Layoffs (19)
Legal (64)
Licensing (2)
Liver cancer (2)
Longevity (2)
Lung cancer (40)
Lymphoma (26)
Machine learning (3)
Management (1)
Manufacturing (39)
Marketing (1)
MASH (2)
Medical device (133)
Medtech (135)
Mergers & acquisitions (354)
Metabolic disorders (41)
mRNA (6)
Neurodegenerative disease (19)
Neuroscience (66)
NextGen: Class of 2026 (173)
Non-profit (41)
Now hiring (4)
Obesity (9)
Opinion (4)
Ovarian cancer (6)
Pain (16)
Pancreatic cancer (3)
Parkinson's disease (9)
Patents (15)
Patient recruitment (21)
Patient selection (2)
People (3256)
Pharmacy benefit managers (1)
Phase 1 (928)
Phase 2 (998)
Phase 3 (598)
Pipeline (410)
Policy (14)
Postmarket research (30)
Preclinical (297)
Press Release (3)
Prostate cancer (5)
Psychedelics (1)
Radiopharmaceuticals (8)
Rare diseases (65)
Real estate (114)
Recruiting (1)
Regenerative medicine (1)
Regulatory (482)
Reports (3)
Research institute (71)
Resumes & cover letters (3)
RSV (1)
Schizophrenia (4)
Series A (27)
Series B (7)
Service/supplier (1)
Sickle cell disease (5)
Special edition (2)
Spinal muscular atrophy (4)
Sponsored (2)
Startups (132)
Supply chain (3)
Tariffs (2)
The Weekly (2)
Vaccines (23)
Venture capital (4)
Weight loss (3)
Women's health (3)
Date
Today (1)
Last 7 days (13)
Last 30 days (63)
Last 365 days (986)
2026 (753)
2025 (1014)
2024 (1235)
2023 (1551)
2022 (1852)
2021 (1891)
2020 (1457)
2019 (922)
2018 (734)
2017 (791)
2016 (655)
2015 (685)
2014 (464)
2013 (366)
2012 (330)
2011 (351)
2010 (373)
Location
Africa (16)
Alabama (2)
Arizona (3)
Asia (1295)
Australia (91)
California (840)
Canada (189)
China (59)
Colorado (7)
Connecticut (13)
Delaware (22)
Europe (1830)
Florida (76)
Georgia (9)
Idaho (1)
Illinois (12)
Indiana (4)
Japan (28)
Kansas (1)
Kentucky (1)
Louisiana (1)
Maryland (88)
Massachusetts (381)
Michigan (5)
Minnesota (10)
Missouri (1)
Montana (2)
Nevada (2)
New Hampshire (1)
New Jersey (103)
New Mexico (3)
New York (83)
North Carolina (28)
Northern California (384)
Ohio (3)
Oklahoma (2)
Pennsylvania (149)
South America (82)
Southern California (359)
Tennessee (1)
Texas (51)
United States (1892)
Utah (3)
Virginia (7)
Washington D.C. (2)
Washington State (23)
Wisconsin (3)
16,830 Results for "sab biotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
October 1, 2026
·
6 min read
Press Releases
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
April 29, 2026
·
4 min read
Press Releases
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
September 22, 2026
·
6 min read
Press Releases
SAB BIO to Participate in Upcoming September 2026 Investor Conferences
September 1, 2026
·
1 min read
Press Releases
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
August 6, 2026
·
11 min read
Press Releases
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
May 29, 2026
·
5 min read
Press Releases
Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases
September 14, 2026
·
2 min read
SAb Biotherapeutics Rebrands as SAB BIO
SAB Biotherapeutics today announced its new name, SAB BIO, and visual identity to more closely align with its mission to treat and prevent immune and autoimmune disorders with the use of its unique immunotherapy platform.
June 20, 2024
·
5 min read
Press Releases
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
July 30, 2026
·
1 min read
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics, Inc. today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA disclosed that SAB has completed dosing the third cohort for SAB-142.
April 16, 2024
·
5 min read
1 of 1,683
Next
